Latest Featured Products

Optimal Medium for T cells, CAR-Ts, TILs, and PBMCs; Serum-free, xeno-free formulation; Ready to use; cGMP manufactured; Supports all T cell populations and other immune cells

T cell-mediated therapies, such as CAR-T or tumor-infiltrating lymphocytes therapies, hold promise to transform cancer treatment to be more personalized and effective. Cytokines have a fundamental role in T cell survival, expansion, and differentiation.

Sino Biological has developed an array of high-quality Proteins, Antibodies, Genes, Lysate, and qPCR Primer Pairs to support the study of IFN-Is.

Sino Biological has developed recombinant MPXV A29 and L1R proteins, and A33R, A35R, and B21R Proteins are coming soon.

Xeno-free, serum-free media for the cultivation of T cells and other immune cells, offering superior performance and flexibility. The media is ready to use and provide excellent performance without the addition of serum.

Natural killer (NK) cells are immune cells capable of killing target cells and can be genetically modified to express chimeric antigen receptors (CARs). CAR NK-cell therapy is an innovative type of cancer immunotherapy for solid tumors and hematological malignancies.

Our TSA Vivid Fluorophore Kits are engineered for increased brightness and improved performance with tyramide signal amplification in IHC, ICC and FISH applications.

As a leading manufacturer of recombinant proteins and other critical reagents to support the development of biomedicine, ACROBiosystems is proud to stand by you in the CGT journey.

Scientists at Pall Life Science assessed the relative merits of Protein A HPLC and Protein A biolayer interferometry (BLI) to determine concentrations of monoclonal antibodies (mAb) in a complex feedstock. The results illustrated that the Octet® BLI system provides a fast, accurate and economical means of quantifying mAbs, and decreases process development efforts.

Whether mixing, temperature control, automation, safety or design - this new bioreactor combines all of IKA's core competencies and yet is a true innovation. With HABITAT, IKA launches its first own bioreactor - with the aim to significantly improve the device and its handling.